MOESM1 of Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial

Tripolt, Norbert; Aberer, Felix; Riedl, Regina; Url, Jasmin; Dimsity, Gudrun; Meinitzer, Andreas; Stojakovic, Tatjana; Aziz, Faisal; Hรถdl, Ronald; Brachtl, Gabriele; Strunk, Dirk; Brodmann, Marianne; Hafner, Franz; Sourij, Harald

doi:10.6084/m9.figshare.6286979.v1

12933_2018_716_MOESM1_ESM.docx (17.6 kB)

MOESM1 of Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial

journal contribution

posted on 2018-05-17, 05:00 authored by Norbert Tripolt, Felix Aberer, Regina Riedl, Jasmin Url, Gudrun Dimsity, Andreas Meinitzer, Tatjana Stojakovic, Faisal Aziz, Ronald Hรถdl, Gabriele Brachtl, Dirk Strunk, Marianne Brodmann, Franz Hafner, Harald Sourij

Additional file 1: Table S1. Change in cell counts from baseline in linagliptin vs. Placebo groups. FMD: flow mediated dilatation; MTT: meal tolerance test; sVCAM-1: soluble vascular cell adhesion molecule-1; sICAM-1: soluble intercellular adhesion molecule-1.

Funding

Oesterreichische Nationalbank

History

Usage metrics

Keywords

Linagliptin Flow mediated dilatation RCT DPP-4 inhibitor Type 2 diabetes Coronary artery disease Endothelial function

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM1 of Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial

Funding

Oesterreichische Nationalbank

History

Usage metrics

Categories

Keywords

Licence

Exports